|
1
|
Canellos GP, Rosenberg SA, Friedberg JW,
Lister TA and Devita VT: Treatment of Hodgkin lymphoma: a 50-year
perspective. J Clin Oncol. 32:163–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner H, Gondos A and Pulte D: Ongoing
improvement in long-term survival of patients with Hodgkin disease
at all ages and recent catch-up of older patients. Blood.
111:2977–1983. 2008. View Article : Google Scholar
|
|
3
|
Carbone PP, Kaplan HS, Musshoff K, et al:
Report of the Committee on Hodgkin’s Disease Staging
Classification. Cancer Res. 31:1860–1861. 1971.PubMed/NCBI
|
|
4
|
Eberl MM, Fox CH, Edge SB, et al: BI-RADS
classification for management of abnormal mammograms. J Am Board
Fam Med. 19:161–164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sobin LH, Gospodarowicz MK and Wittekind
C: Colon and rectum. TNM Classification of Malignant Tumours. 7th
edition. Wiley-Blackwell; pp. 100–106. 2009
|
|
6
|
Reis LAG, Melbert D, Krapcho M, et al;
National Cancer Institute. SEER cancer statistics review,
1975–2004. http://seer.cancer.gov/csr/1975_2004/.
Accessed April 8, 2014
|
|
7
|
Arseneau JC, Sponzo RW, Levin DL, et al:
Nonlymphomatous malignant tumors complicating Hodgkin’s disease.
Possible association with intensive therapy. N Engl J Med.
287:1119–1112. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Canellos GP, Arseneau JC, DeVita VT,
Whang-Peng J and Johnson RE: Second malignancies complicating
Hodgkin’s disease in remission. Lancet. 1:947–949. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hodgson DC, Gilbert ES, Dores GM, et al:
Long-term solid cancer risk among 5-year survivors of Hodgkin’s
lymphoma. J Clin Oncol. 25:1489–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Franklin J, Pluetschow A, Paus M, et al:
Second malignancy risk associated with treatment of Hodgkin’s
lymphoma: meta-analysis of the randomised trials. Ann Oncol.
17:1749–1760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Henry-Amar M and Somers R: Survival
outcome after Hodgkin’s disease: a report from the international
data base on Hodgkin’s disease. Semin Oncol. 17:758–768.
1990.PubMed/NCBI
|
|
12
|
Cosset JM, Henry-Amar M and Meerwaldt JH:
Long-term toxicity of early stages of Hodgkin’s disease therapy:
the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol.
2(Suppl 2): 77–82. 1991. View Article : Google Scholar
|
|
13
|
Mauch PM, Kalish LA, Marcus KC, et al:
Long-term survival in Hodgkin’s disease relative impact of
mortality, second tumors, infection, and cardiovascular disease.
Cancer J Sci Am. 1:33–42. 1995.PubMed/NCBI
|
|
14
|
Hoppe RT: Hodgkin’s disease: complications
of therapy and excess mortality. Ann Oncol. 8:115–118. 1997.
View Article : Google Scholar
|
|
15
|
Aleman BM, van den Belt-Dusebout AW,
Klokman WJ, Bartelink H, Van’t Veer MB and van Leeuwen FE:
Long-term cause-specific mortality of patients treated for
Hodgkin’s disease. J Clin Oncol. 21:3431–3439. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Henry-Amar M: Second cancer after the
treatment for Hodgkin’s disease: a report from the International
Database on Hodgkin’s Disease. Ann Oncol. 3(Suppl 4): 117–128.
1992. View Article : Google Scholar
|
|
17
|
Swerdlow AJ, Douglas AJ, Vaughan Hudson G,
et al: Risk of second primary cancers after Hodgkin’s disease by
type of treatment: analysis of 2,846 patients in the British
National Lymphoma Investigation. Brit Med J. 304:1137–1143. 1992.
View Article : Google Scholar
|
|
18
|
Abrahamsen JF, Andersen A, Hannisdal E, et
al: Second malignancies after treatment of Hodgkin’s disease: the
influence of treatment, follow-up time, and age. J Clin Oncol.
11:255–261. 1993.PubMed/NCBI
|
|
19
|
van Leeuwen FE, Klokman WJ, Hagenbeek A,
et al: Second cancer risk following Hodgkin’s disease: a 20-year
follow-up study. J Clin Oncol. 12:312–325. 1994.PubMed/NCBI
|
|
20
|
Dores GM, Metayer C, Curtis RE, et al:
Second malignant neoplasms among long-term survivors of Hodgkin’s
disease: a population-based evaluation over 25 years. J Clin Oncol.
20:3484–3494. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hancock SL, Tucker MA and Hoppe RT: Breast
cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst.
85:25–31. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ibrahim EM, Abouelkhair KM, Kazkaz GA,
Elmasri OA and Al-Foheidi M: Risk of second breast cancer in female
Hodgkin’s lymphoma survivors: a meta-analysis. BMC Cancer.
12:1972012. View Article : Google Scholar
|
|
23
|
Crump M and Hodgson D: Secondary breast
cancer in Hodgkin’s lymphoma survivors. J Clin Oncol. 27:4229–4231.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
De Bruin ML, Sparidans J, Van’t Veer MB,
et al: Breast cancer risk in female survivors of Hodgkin’s
lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol.
27:4239–4246. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cooke R, Jones ME, Cunningham D, et al;
England and Wales Hodgkin Lymphoma Follow-up Group. Breast cancer
risk following Hodgkin lymphoma radiotherapy in relation to
menstrual and reproductive factors. Br J Cancer. 108:2399–2406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Travis LB, Curtis RE and Boice JD Jr: Late
effects of treatment for childhood Hodgkin’s disease. N Engl J Med.
335:352–353. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Milano MT, Li H, Gail MH, et al: Long-term
survival among patients with Hodgkin’s lymphoma who developed
breast cancer: a population-based study. J Clin Oncol.
28:5088–5096. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elkin EB, Klem ML, Gonzales AM, et al:
Characteristics and outcomes of breast cancer in women with and
without a history of radiation for Hodgkin’s lymphoma: a
multi-institutional, matched cohort study. J Clin Oncol.
29:2466–2473. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dores GM, Anderson WF, Beane Freeman LE,
Fraumeni JF Jr and Curtis RE: Risk of breast cancer according to
clinicopathologic features among long-term survivors of Hodgkin’s
lymphoma treated with radiotherapy. Br J Cancer. 103:1081–1084.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Veit-Rubin N, Rapiti E, Usel M, et al:
Risk, characteristics, and prognosis of breast cancer after
Hodgkin’s lymphoma. Oncologist. 17:783–791. 2012. View Article : Google Scholar :
|
|
31
|
Ng AK, Bernardo MV, Weller E, et al:
Second malignancy after Hodgkin disease treated with radiation
therapy with or without chemotherapy: long-term risks and risk
factors. Blood. 100:1989–1996. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ibrahim EM, Kazkaz GA, Abouelkhair KM,
Al-Mansour MM, et al: Increased risk of second lung cancer in
Hodgkin’s lymphoma survivors: a meta-analysis. Lung. 191:117–134.
2013. View Article : Google Scholar
|
|
33
|
Xu Y, Wang H, Zhou S, et al: Risk of
second malignant neoplasms after cyclophosphamide-based
chemotherapy with or without radiotherapy for non-Hodgkin lymphoma.
Leuk Lymphoma. 54:1396–1404. 2013. View Article : Google Scholar
|
|
34
|
Youn P, Li H, Milano MT, Stovall M,
Constine LS and Travis LB: Long-term survival among Hodgkin’s
lymphoma patients with gastrointestinal cancer: a population-based
study. Ann Onocol. 24:202–208. 2013. View Article : Google Scholar
|
|
35
|
Swerdlow AJ, Higgins CD, Smith P, et al:
Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a
collaborative British cohort study. J Clin Oncol. 29:4096–4104.
2011. View Article : Google Scholar : PubMed/NCBI
|
